Patents for A61P 35 - Antineoplastic agents (221,099)
04/2007
04/18/2007CN1950376A Curcumol derivatives, compositions comprising the same and use in manufacture of medicament
04/18/2007CN1950372A 咪唑并吡啶化合物 Imidazopyridine compound
04/18/2007CN1950369A Novel benzothiazoles and the use thereof as medicaments
04/18/2007CN1950367A 2-styryl-4-oxazole-methanol-ethers and their use as tyrosine kinase inhibitors
04/18/2007CN1950366A Thioether derivatives, their manufacture and use as pharmaceutical agents
04/18/2007CN1950343A Basic amine compound and use thereof
04/18/2007CN1950341A Naphthalimide derivatives for the treatment of cancer
04/18/2007CN1950111A Activatable particles, preparations and uses.
04/18/2007CN1950094A Composition comprising a survivin antisense oligonucleotide and gemcitabine for the treatment of cancer
04/18/2007CN1950088A Use of carboxypeptidase G for combating antifolate toxicity
04/18/2007CN1950083A Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
04/18/2007CN1948502A Application of TRPC in screening antitumour medicine and medical use of its inhibitor
04/18/2007CN1948494A Prostate gland cancer cell specificity promotor and its application
04/18/2007CN1948484A siRNA for inhibiting human hPEBP4 gene expression and its application
04/18/2007CN1948483A SiRNA for inhibiting human Rabj gene expression and its application
04/18/2007CN1948482A Antisensedigonucleotides sequence for inhibiting human Rabj gene expression and its application
04/18/2007CN1948477A Preparation method of gene recombination fusion protein PFK
04/18/2007CN1948342A HLA-A2 restriction epi polypeptide originated from post selection cancer gene hRabj and its application
04/18/2007CN1948337A Preparation method of wheat germ agglutinin and its application in inhibiting mammary gland cancer activity
04/18/2007CN1948333A New hPEBP4 protein source HLA-A2 limiting epi-polypeptide and its application
04/18/2007CN1948323A Platinum (II)- anticancer compound using 2-hydroxy-1,3-propane diamine as carrier group
04/18/2007CN1948313A Preparation method of tiemoazoleamine-8-carboxylic acid water soluble derivative, anticancer activity and application in preparing anticancer medicine
04/18/2007CN1948304A Heteraryl ring thiosemicarbazone kind compound and its derivative
04/18/2007CN1948275A Verakanol Mannich alkali derivative, its preparation method and use
04/18/2007CN1948274A Verakanol derivative, its preparation method and use
04/18/2007CN1948248A Wheat bran total alkyl phenol extract and its preparation method and application
04/18/2007CN1947795A Method for preparing composite nano-polymers to inhibit tumor multidrug resistance
04/18/2007CN1947793A Application of Entamoeba histolytica for treating malignant noumenal tumor
04/18/2007CN1947792A Method for preparing active protein composition type nano-selenium and its liquid phase storage tech.
04/18/2007CN1947789A Traditional Chinese medicine Shenshu capsule
04/18/2007CN1947788A Formula of Zhi-Ai-Hua-Yi-Wan traditional Chinese medicine for treating cancer and its prepn. method
04/18/2007CN1947769A Medicine for treating esophagus cancer and cardia cancer and its prepn. method
04/18/2007CN1947733A Soft capsule prepn. contg. Sarcandra glaber, and its prepn. method
04/18/2007CN1947723A Liquid polysaccharide, glycan nano-selenium, prepn. method and storage method thereof
04/18/2007CN1947722A Blood sugar regulator used during user having meals and its prepn. method
04/18/2007CN1947721A Method for preparing epirubicin slow-release prepn
04/18/2007CN1947720A Clarithromycin liposome microsphere injection and its prepn. method
04/18/2007CN1947718A Cucurbitacin dispersion tablets and its prepn. method
04/18/2007CN1947714A Oridonin clathrate compound, and medicinal prepn. thereof
04/18/2007CN1947704A Medicinal water-soluble compositions contg. 20(R)-ginsenoside (Rg3), and its prepn. method
04/18/2007CN1947703A Stable elaioplast compositions
04/18/2007CN1947701A Solid self-micro emulsion contg. jervic alcohol for antineoplastic medicine and its prepn. method
04/18/2007CN1310948C Modified peptides as therapeutic agents
04/18/2007CN1310937C Sir2 products and activities
04/18/2007CN1310932C N-crotonoyl hydroxy protected glucosamine and its prepn and application
04/18/2007CN1310921C Bicyclic oxopyridine and oxopyrimidine derivatives
04/18/2007CN1310918C Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
04/18/2007CN1310908C Rapamycin 29-enols
04/18/2007CN1310907C Heterocyclic compound and antitumour agent containing the same as active ingredient
04/18/2007CN1310904C Tricyclic alkylhydroxamates, their preparation and thier use as well proliferation inhibitors
04/18/2007CN1310900C Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing the same
04/18/2007CN1310898C Taxinol water soluble derivative
04/18/2007CN1310870C Enantiomerically enriched 1-phenylethylamines
04/18/2007CN1310672C Osteogenis oligopeptide as blood-formation stimulation articles
04/18/2007CN1310654C Medicament for treatment of gynecologic diseases and preparation method
04/18/2007CN1310642C Methods and compositions to enhance white blood cell count
04/17/2007USRE39574 Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
04/17/2007USRE39573 Antimutagenic compositions for treatment and prevention of photodamage to skin
04/17/2007US7205403 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
04/17/2007US7205392 Synergistic mixture of glycoprotein and angiogenesis inhibitor
04/17/2007US7205386 Truncated CD200
04/17/2007US7205383 Peptide ligands of leukocyte integrins
04/17/2007US7205327 Benzoimidazole or imidazole-2-carbonyl)-amino)-3-methyl butyrylamino)-5-fluoro-4-oxo- derivatives
04/17/2007US7205326 Tyrosine inhibitor inhibitors; anticancer agents
04/17/2007US7205325 Oxazole derivatives
04/17/2007US7205324 IMPDH (inosine-5'-monophosphate dehydrogenase); transplant rejection and autoimmune diseases
04/17/2007US7205312 As inhibitors of the retinoic acid-metabolism, as drugs; breast cancer; psoriasis
04/17/2007US7205311 Therapeutic acridone and acridine compounds
04/17/2007US7205304 medicine to inhibit proliferative conditions, such as cancer and psoriasis
04/17/2007US7205300 Aryl fused azapolycyclic compounds
04/17/2007US7205298 Substituted triazine kinase inhibitors
04/17/2007US7205287 Platinum complexes having antitumor activity
04/17/2007US7205286 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
04/17/2007US7205284 Potent immunostimulants from microalgae
04/17/2007US7205283 Antisense oligonucleotides that inhibit expression of HIF-1
04/17/2007US7205275 Methods of treatment using specific binding agents of human angiopoietin-2
04/17/2007US7205274 Hybrid peptides modulate the immune response
04/17/2007US7205151 Antiinflammatory agents; skin disorders
04/17/2007US7205139 Expression vector comprising nucleotide sequences coding serine protease for use in diagnosis and treatment of thrombotic disorders
04/17/2007US7205126 Made by disrupting HPV-virus-like particles including a chelating agent, mixing them with plasmids and reassembling them into the pseudoviruses (VLPs with plasmids inside) adding a stop buffer to reassemble the VLPs into pseudoviruses; administering to the mucosa; can be applied in gene therapy
04/17/2007US7205125 Mixed Virus-like particles
04/17/2007US7205119 HA-1 antigen
04/17/2007US7205113 Regulation of T cell responses, T cell proliferation, and induction of T cell death
04/17/2007US7205108 Trp8, Trp9 and Trp10, novel markers for cancer
04/17/2007US7205001 Anticancer agents; using potassium arsenite therapy and radiation
04/17/2007CA2386799C Fused cycloheptane and fused azacycloheptane compounds and their as integrin receptor antagonists
04/17/2007CA2371645C Naphtalene or heterocyclically substituted benzimidazoles as parp inhibitors
04/17/2007CA2348725C Vitamin d analogues
04/17/2007CA2341690C Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
04/17/2007CA2271085C Indolecarboxylic compounds and their use as pharmaceutical compounds
04/17/2007CA2250586C Meta-substituted phenylene sulphonamide derivatives
04/17/2007CA2196197C Retinoic acid x-receptor ligands
04/17/2007CA2190765C Novel potent inducers of terminal differentiation and methods of use thereof
04/17/2007CA2184175C Isolated, tyrosinase derived peptides and uses thereof
04/17/2007CA2124260C Tetrahydropyran derivatives
04/17/2007CA2106819C Oligoribonucleotide and ribozyme analogs with terminal 3'-3' and/or 5'-5' linkages
04/12/2007WO2007041712A1 Pyrazolopyrimidines as protein kinase inhibitors
04/12/2007WO2007041379A1 Met kinase inhibitors
04/12/2007WO2007041362A1 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
04/12/2007WO2007041357A1 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors